CervoMed (NASDAQ:CRVO) Upgraded at Chardan Capital
Chardan Capital upgraded shares of CervoMed (NASDAQ:CRVO – Free Report) from a neutral rating to a buy rating in a report issued on Thursday morning, MarketBeat Ratings reports. Chardan Capital currently has $14.00 target price on the stock. Several other analysts also recently issued reports on the company. Brookline Capital Management raised CervoMed from a […]
